Showing results (101-110 of 119) with videos related to
Sort By:
Pageof 12
Plos One|May 17, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimensSilvia Querings, Janine Altmüller, Sascha Ansén, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Blood-based gene expression signatures in non-small cell lung cancerThomas Zander, Andrea Hofmann, Andrea Staratschek-Jox, et al.The Lancet. Oncology|October 25, 2011
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialElisabeth Quoix, Rodryg Ramlau, Virginie Westeel, et al.Digestive Diseases (Basel, Switzerland)|February 16, 2025
Gastrointestinal Ultrasound: Measurements and Normal Findings - What Do You Need to Know?Kathleen Möller, Pascal Fischer, Odd Helge Gilja, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2014
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lungHans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.Oncotarget|December 5, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignanciesMatthias Scheffler, Marc Bos, Masyar Gardizi, et al.Endocrinology|December 30, 2025
Metformin in Obese Pregnancy: Developmental Reprogramming of Offspring Liver and MASLD Risk by Age and SexElena Müller-Limberger, Bettina Frederick, Sebastian Hansen, et al.European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2012
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancerHans-Ulrich Schildhaus, Lukas C Heukamp, Sabine Merkelbach-Bruse, et al.Pageof 12